Since the beginning of the pandemic, CRP, and IL6 levels have been used as prognostic biomarkers in COVID-19; in addition, IL6 activity has been targeted for treatment by the anti-IL-6 receptor antibody but also to guide treatment and predict response to tocilizumab (8, 20, 21). The gene discussed is CRP; the disease is COVID-19.